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Dengue fever is a mosquito-borne viral disease prevalent mainly in tropical countries. As the clinical
manifestations of dengue are not very unique, laboratory diagnosis is crucial in identifying cases of dengue
infection. Detection of dengue infection based on the identification of antidengue antibodies has emerged as a
practical and reliable means of diagnosing dengue fever. We recently developed a customized recombinant
dengue multiepitope protein (r-DME-G) that can specifically detect the immunoglobulin G (IgG) class of
antidengue antibodies in patient sera. Using this strategy, we have now created another dengue multiepitope
protein, r-DME-M, with specificity for the IgM class of antidengue antibodies. A synthetic gene encoding the
r-DME-M protein was expressed as a maltose-binding protein fusion in Escherichia coli. The recombinant
protein was purified in a single affinity chromatographic step to obtain yields of 15 mg purified protein/liter
of culture. The purified protein was used to develop an in-house IgM enzyme-linked immunosorbent assay
(ELISA) and tested using a panel of 172 patient sera characterized using the commercially available Dengue
Duo rapid strip test from PanBio, Australia. The IgM ELISA results showed that the r-DME-M protein not
only recognized all IgM samples identified by the PanBio test but also identified samples missed by the latter
test. We also successfully adapted the r-DME-M protein to a rapid strip test format. This approach of creating
customized antigens coupled to overexpression in E. coli and simple purification offers a promising alternative
option to dengue diagnosis with the potential to circumvent the drawbacks of the whole virus antigen-based
commercial kits.
Infection with dengue (DEN) viruses, of which there are
four closely related but antigenically distinct serotypes (DEN-1,
-2, -3 and -4), can cause a whole spectrum of illness ranging
from the relatively mild dengue fever (DF) to potentially fatal
dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS). The disease is transmitted to humans by mosquitoes
and represents a major, rapidly expanding global public health
problem in more than 100 nations worldwide. Annually, about
100 million people are infected, of which about 500,000, mostly
children, are affected by DHF/DSS. The World Health Orga-
nization estimates that about 2.5 billion people are at risk of
dengue infection (7–9). The at-risk population is predicted to
double in the coming years (10). The high case fatality rates
associated with DHF/DSS can be significantly minimized by
supportive care and symptomatic treatment through fluid re-
placement. The key to survival therefore depends on early,
definitive diagnosis of dengue infection (17, 21). In this con-
text, the detection of dengue infections through identification
of antidengue antibodies in the serum has emerged as a very
reliable diagnostic approach (7).
The immunological status of the infected individual determines
if the antidengue antibody response is primary or secondary (19).
While individuals previously unexposed to flaviviral infection
mount a primary antibody response, those who have experienced
prior flavivirus infection manifest a secondary antibody response.
In primary infection, anti-dengue immunoglobulin M (IgM) an-
tibodies appear as early as 3 to 5 days after onset of illness, peak
at about 2 weeks postinfection, and wane thereafter. IgG anti-
bodies appear shortly afterwards and persist for several years. In
contrast, secondary infection is characterized by the appearance
of high-titer antidengue IgG antibodies, which appear either be-
fore or along with IgM antibodies. While the kinetics of IgM
production is similar in primary and secondary infections, IgM
antibody titers tend to be significantly lower in the latter instance.
This difference in the pattern of antibody response has provided
the basis for the serological detection of IgM and IgG antidengue
antibodies to differentiate between primary and secondary den-
gue infections (19).
In recent years, several dengue diagnostic kits, in a multiplicity
of formats, have become commercially available (6). These are
used primarily to screen travelers returning from countries where
dengue is endemic. Some of these kits can detect both antidengue
IgM and IgG antibodies simultaneously and distinguish between
primary and secondary dengue infections. Many of the diagnostic
tests use whole virus antigen, produced in tissue culture or suck-
ling mouse brain, for antidengue antibody detection. The use of
such material, while presenting a potential health hazard through
exposure to infectious virus, is also expensive, as production costs
associated with virus cultivation are generally high. Further, the
whole virus antigens manifest cross-reactivity towards antibodies
against other flaviviruses as well as unrelated infectious agents,
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resulting in false positivity (6). One way to address these concerns
is to replace the whole virus antigens with customized recombi-
nant antigens, consisting of carefully chosen epitopes. Immuno-
dominant, linear dengue viral epitopes, potentially suitable for
constructing multiepitope proteins, have been mapped exten-
sively on the major structural protein, the envelope (E) protein
(12, 15, 20), and the nonstructural (NS) protein NS1 (3, 4, 22, 23).
The majority of these epitopes specifically recognize IgG
antibodies.
We recently reported a novel multiepitope approach that
entails splicing together unique dengue-specific epitopes that
do not cross-react with antibodies to non-dengue flavivirus
antibodies and overexpressing the resultant recombinant pro-
tein in an Escherichia coli host (1). The multiepitope approach,
which eliminates the whole virus antigen (thus contributing to
safety), permits a high epitope density (sensitivity), careful
choice of unique dengue-specific epitopes (specificity), and E.
coli-based overexpression (cost-effective antigen production).
Using this approach we created a recombinant dengue multi-
epitope protein, r-DME-G, by fusing together several IgG-spe-
cific dengue virus-encoded epitopes. Further, we demonstrated
that this protein could be used in an indirect enzyme-linked
immunosorbent assay (ELISA) to specifically detect an anti-
dengue IgG class of antibodies in patient sera (1).
We have now used this approach to develop a new recom-
binant dengue multiepitope protein, designed to detect IgM-
specific antidengue antibodies. A thorough examination of the
available literature revealed a single report by Huang et al.
(11) that described an IgM-specific dengue epitope that ap-
peared potentially useful for the purpose of creating an IgM-
specific dengue multiepitope protein. These investigators ex-
amined potential B-cell epitope-containing peptides of DEN-2
NS1 for their reactivity to IgM and IgG classes of antibodies in
dengue and Japanese encephalitis (JE) patient sera. They
identified a single peptide, D2 NS1-P1, which reacted with the
IgM class of antibodies in sera of dengue, but not JE, patients.
This peptide, corresponding to amino acid (aa) residues 1 to 15
of DEN-2 NS1, defined a linear, immunodominant IgM-spe-
cific epitope which was reactive towards patient sera from all
four dengue serotypes (11). We used this epitope as the basis
for designing the recombinant dengue multiepitope protein,
r-DME-M, with built-in specificity for the IgM class of anti-
dengue antibodies. In this paper, we describe the design of the
r-DME-M protein, its expression, and purification. Further, we
present data demonstrating its utility as a diagnostic reagent in
the detection of antidengue IgM antibodies. Finally, we de-
scribe the design of a simple strip test using the r-DME-M
protein that could prove useful in identifying dengue infections
under field conditions where adequate diagnostic facilities may
be lacking.
MATERIALS AND METHODS
Materials. Escherichia coli host strain DH5 was purchased from Invitrogen.
The plasmid pQE60 (Ampr), Ni-nitrilotriacetic acid (NTA) superflow resin and
anti-His monoclonal antibody (catalog no. 34660) were from QIAGEN, Ger-
many. The plasmid pMALc2x was purchased from New England Biolabs. The
secondary antibody-enzyme conjugates (anti-mouse IgG–alkaline phosphatase
[AP] and anti-human IgM–horseradish peroxidase [HRPO]) and the AP sub-
strate 5-bromo-4-chloro-3-indolyl phosphate–nitroblue tetrazolium (BCIP/NBT)
were from Calbiochem. The HRPO substrate 3,3,5,5-tetramethylbenzidine
(TMB) was from Kirkegaard & Perry Laboratories.
Construction of the r-DME-M gene expression vector. A synthetic gene,
codon-optimized for E. coli expression, was first generated by ligation (GeneArt,
Germany) of oligonucleotides encoding four linear immunodominant epitopes
from NS1 proteins of DEN serotypes 1 to 4. These epitopes were 15 aa residues
long with adjacent epitopes joined together by tetraglycyl linkers. The resultant
0.24-kb gene, the r-DME-M gene, was ligated into the BamHI and BglII sites of
the bacterial expression vector pQE-60 to generate the plasmid pQ-r-DME-M.
In this plasmid, the r-DME-M gene was inserted in frame with the ATG codon
(at the 5 end) and the six-His tag-encoding sequence (at the 3 end) provided by
the pQE-60 vector. Recombinant clones were selected on ampicillin plates and
subjected to direct colony PCR screening, using vector-specific primers, to iden-
tify recombinants harboring the synthetic r-DME-M gene. Orientation of the
insert was verified by restriction analysis of plasmid minipreps. The r-DME-M
gene plus the six-His tag-encoding sequence were retrieved from the pQ-
rDME-M construct as a 0.26-kb BamHI/HindIII restriction fragment and ligated
in frame with the malE gene of plasmid pMALc2x. In this vector, the malE gene,
which encodes the maltose-binding protein (MBP), is driven by the isopropyl-
thiogalactoside (IPTG)-inducible Ptac promoter. The ligated product was trans-
formed into E. coli DH5 cells and selected on ampicillin plates. The resultant
DH5 transformants were screened by restriction analysis. Positive clones were
further subjected to expression screening (see below) to identify clones capable
of efficiently expressing the r-MBP-DME-M fusion protein.
Expression screening. Expression screening was done using test tube cultures,
essentially as described earlier (1). Several of the positive DH5 clones, chosen
based on restriction analysis, were inoculated into 3-ml test tube cultures and
allowed to grow at 37°C in a shaker at 200 rpm. When the cultures were in
logarithmic growth phase (corresponding to an optical density at 600 nm [OD600]
of 0.6), they were induced with 0.4 mM IPTG for 4 h. After induction,
equivalent numbers of cells from the different cultures (normalized on the basis
of OD600 values) were lysed in sample buffer and analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (14). Noninduced con-
trols were analyzed in parallel. One clone that expressed maximal levels of the
recombinant protein was chosen for further work. Plasmid DNA isolated from
this clone was verified by restriction analysis.
Purification of r-DME-M protein. A preculture was set up by inoculating 20 ml
LB medium containing ampicillin (100 g/ml) with 10 l glycerol stock of a
DH5 clone (chosen above) harboring the r-MBP-DME-M gene. The culture was
grown overnight in a shaker at 37°C, at 200 rpm, and inoculated into 1 liter LB
(containing 100 g ampicillin/ml), in a 4-liter Haffkine flask, which was placed in
the shaker at 37°C for about 2 to 3 h at 125 rpm. When the OD600 of the culture
reached 0.6 (a small aliquot of the noninduced culture was set aside for
subsequent SDS-PAGE analysis), it was induced by the addition of IPTG to a
final concentration of 0.4 mM. Induction was allowed to proceed for 4 h before
harvesting the cells. Aliquots of the induced and noninduced cell cultures were
analyzed by SDS-PAGE prior to initiating purification.
The induced culture was centrifuged in a Sorvall GS3 rotor at 6,000 rpm for 15
min at 4°C. About 1 g of induced cell pellet (corresponding to 250 ml E. coli
culture) was lysed by stirring in 10 ml lysis buffer (8 M urea–100 mM sodium
phosphate–10 mM Tris-HCl–10 mM imidazole [pH 8.0]), at room temperature
(RT) for 1 h. The lysate was clarified by centrifugation (10,000 rpm in a Sorvall
GSA rotor at RT for 30 min). The resultant supernatant was mixed with 1 ml
Ni-NTA Superflow resin that had been preequilibrated with the lysis buffer. This
suspension was gently rocked for 1 h at RT and then packed into a column. After
collecting the flowthrough, the column was washed extensively with buffer 1 (lysis
buffer containing 20 mM imidazole) and eluted with buffer 2 (lysis buffer con-
taining 250 mM imidazole). Fractions of 3 ml were collected and analyzed by
SDS-PAGE. Peak fractions were pooled together, mixed with gentamicin to a
final concentration of 50 g/ml, flash-frozen in liquid nitrogen, and stored at
80°C until use.
Western blot analysis. The procedure adopted was identical to that reported
earlier by us for r-DME-G protein (1). The purified r-DME-M protein was run
on a 15% denaturing gel (SDS-PAGE), along with appropriate controls and
prestained protein markers, and transferred electrophoretically to a nitrocellu-
lose membrane. The membrane was blocked with 1% polyvinyl pyrrolidone in
1 phosphate-buffered saline, pH 7.2 (PBS) for 2 h at RT. It was then washed
three times with 1 PBS containing 0.1% Tween 20 (1 PBS plus 0.1% T) and
incubated with a commercially available murine penta-His monoclonal antibody
(MAb; 1:2,000 dilution) for 90 min at RT. The membrane was washed again, as
above, and incubated with anti-mouse IgG–AP conjugate (1:5,000 dilution) for a
further 90 min at RT. The blot was washed and developed by incubation in
BCIP/NBT substrate solution for 15 min at RT.
In-house ELISA for the detection of antidengue IgM antibodies. Again, the
IgM ELISA protocol we used was essentially similar to the one developed earlier
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for the r-DME-G (1), with the only differences being the nature of the coating
antigen and the specificity of the secondary antibody conjugate. Briefly, the
purified r-DME-M protein (diluted to 10 g/ml in 0.1 M carbonate buffer, pH
9.5) was used to coat 96-well microtiter plates (100 l/well) at 4°C overnight. The
coated wells were washed once with 1 PBS plus 0.1% T and blocked with 5%
skim milk powder (SMP) in 1 PBS (1 PBS plus 5% SMP) for 4 h at 37°C. The
wells were washed once again with 1 PBS plus 0.1% T and then incubated for
15 min at 37°C with 100 l dengue patient sera (at a 1:10 dilution in 1 PBS plus
5% SMP containing 1% sodium deoxycholate [SDC]). Wells were washed using
1 PBS plus 0.1% T plus 1% SDC and incubated with murine anti-human
IgM–HRPO conjugate (at a 1:7,500 dilution). The wells were washed once again
as above and incubated with 100 l of TMB substrate for 15 min at 37°C. A
peroxidase reaction was terminated with 100 l 1 M H2SO4, and the absorbance
was read at 450 nm. Control experiments in which we either omitted the addition
of dengue patient serum or used r-MBP as the coating antigen (instead of the
r-MBP-DME-M fusion protein) were run in parallel to correct for any nonspe-
cific ELISA reactivity. Sera were designated as positive or negative for the
presence of antidengue IgM antibodies using a cutoff absorbance of 0.25 (450
nm). This cutoff value was obtained from the mean ELISA absorbance of 59
“normal” sera (that tested negative for both IgM and IgG antibodies using the
PanBio test) plus twice the standard deviation.
Design of an in-house rapid strip test. For this test, we prepared gold-labeled
r-DME-M, test sample, and the test strip as follows. Purified r-DME-M was
conjugated to 40-nm gold colloid using a standardized protocol of British Biocell
International, Cardiff, United Kingdom. The test sample was prepared by pre-
incubating the patient sera (30 l) with gold-conjugated r-DME-M (15 l) in a
final volume of 50 l made up with 1 PBS plus 0.1% T. The test strip (available
from a local vendor), which was a 12-cm strip of nitrocellulose membrane
mounted on a plastic support and provided with an absorbent pad at one end
(the top end while performing the test), was prepared by placing two horizontal
streaks across its mid-section. One streak was of the purified r-DME-M protein,
while the other was of murine anti-r-DME-M polyclonal serum. The relative
positions of these two streaks on the strip are indicated below in Fig. 5A. To
perform the test, the lower, nonpadded end of the strip was dipped into a
microtiter well containing 50 l of the test sample prepared as described above.
About 10 min later, when the sample reached the absorbent pad (which
prevents the sample from running down the strip), the strip was washed in 1
PBS plus 0.1% T and read by visual inspection while still wet. Two pink lines at
both the test and control positions indicated a positive test, while a single pink
line at the control position alone indicated a negative test.
RESULTS
Design of a novel IgM-specific dengue multiepitope protein
(r-DME-M). In order to create a multiepitope protein that
could be useful in early detection of dengue infection, we
focused on an immunodominant epitope of the DEN-2 NS1
protein. This epitope, corresponding to the N-terminal 15 aa
residues, was shown to display predominantly IgM specificity
and was reactive towards sera from patients infected with all
four DEN virus serotypes (11). A sequence alignment of this
peptide with the corresponding regions from the NS1 proteins
of DEN-1, DEN-3, and DEN-4, depicted in Fig. 1A, revealed
a high degree of homology among these four NS1 peptides. We
designed a synthetic gene based on these four epitopes. Adja-
cent epitopes were linked by a string of four glycyl residues. A
synthetic gene encoding this protein, codon optimized for ex-
pression in E. coli, was created and cloned into the bacterial
expression vector pQE60. The insert was designed to be in
frame with the initiator codon and a carboxy-terminal six-
histidine tag-encoding sequence provided by the vector. The
synthetic gene, designated rDME-M (recombinant dengue
multiepitope, IgM specific), is predicted to encode a 9-kDa
recombinant protein. The aa sequence of the r-DME-M pro-
tein is shown in Fig. 1B. A computer modeling analysis of the
structure of the r-DME-M protein, depicted in Fig. 1C, sug-
gested that the proposed design of the multiepitope protein
would be consistent with a structure that permits easy accessi-
bility of all the constituent epitopes.
We transformed the pQ-r-DME-M construct into E. coli host
strain SG13009 containing the pREP4 plasmid, which encodes
the lacI repressor (required for regulated recombinant gene ex-
pression) and the kanamycin marker. Expression screening of
several of the resultant double recombinants failed to identify a
single clone capable of expressing the r-DME-M gene (data not
shown). Given that we had codon optimized our gene for E. coli
expression and had successfully used this vector system and clon-
ing strategy earlier (1), the observed lack of expression is puzzling.
Based on information in the literature that recombinant proteins
of 100 to 200 aa residues are more likely to be expressed effi-
ciently in E. coli (5), it is probable that the failure to express the
r-DME-M protein (88 aa residues) is a reflection of its relatively
smaller size.
Expression of the r-DME-M protein as an MBP fusion. As
attempts to express the r-DME-M protein in E. coli using the
pQE expression plasmid were unsuccessful, we explored the
possibility of expressing it as an MBP fusion. To this end, we
retrieved the r-DME-M gene as a 0.26-kb BamHI/HindIII frag-
FIG. 1. Design of the r-DME-M protein. (A) Multiple sequence
alignment (ClustalW) of the amino-terminal 15 aa residues (single
letter code) of the NS1 proteins of DEN serotypes 1 to 4 (D1 to D4).
Conserved residues are shown in gray boxes. (B) Complete amino acid
sequence of the r-DME-M protein assembled from the peptides indi-
cated in panel A. The epitope amino acids are shown in normal font,
and the tetraglycyl linkers are shown in bold font. The amino-terminal
residues 1 to 4 and the carboxy-terminal eight residues, inclusive of the
six-His tag, shown in italics, are encoded by plasmid-derived se-
quences. (C) A computer-generated representation of the r-DME-M
protein in solution. The protein aa sequence was submitted to the
3D-PSSM web server and visualized using ViewerLite software. Re-
gions in red are -helical, and those in white are unstructured.
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ment (inclusive of the 3 six-histidine tag-encoding sequence)
from the pQ-r-DME-M plasmid and fused it in frame with the
MBP-encoding malE gene in the vector pMALc2x. This ex-
pression vector is depicted in Fig. 2A. In this vector, the MBP-
r-DME-M fusion gene is under the transcriptional control of
the IPTG-inducible Ptac promoter. This vector was introduced
into the E. coli host DH5, and transformants selected in the
presence of ampicillin were analyzed by expression screening.
In this experiment, IPTG-induced cells were directly lysed in
Laemmli sample buffer and analyzed by SDS-PAGE. The
MBP fusion strategy resulted in successful expression. Figure
2B depicts the induction profile of a typical clone. Induction of
the MBP-rDME-M gene resulted in the appearance of a new
52-kDa band, consistent with the predicted size of the MBP-
r-DME-M fusion protein (MBP component, 43 kDa;
r-DME-M component, 9 kDa). When induced cells were
lysed by sonication in a native buffer, separated into super-
natant and pellet fractions as described before (13), and
analyzed by SDS-PAGE, the protein was found to be
present partially in the soluble fraction (30%) with the
rest in the insoluble fraction (compare lanes 2 and 3 in
Fig. 2C). For the sake of convenience, the 52-kDa MBP-
r-DME-M fusion protein is referred to as the r-DME-M
protein in the rest of this paper.
FIG. 3. Purification and characterization of the r-DME-M protein. (A) SDS-PAGE analysis of Ni-NTA affinity column fractions obtained
during the purification of r-DME-M protein. Samples analyzed in the gel are load (L, lane 2), flowthrough (F, lane 3), wash (W1 and W2, lanes
4 and 5), and eluates (E1 to E3, lanes 6 to 8). Protein molecular mass markers (M) were run in lane 1; their sizes in kDa are shown to the left.
The arrow at the right indicates the position of the r-DME-M protein. (B) Western blot analysis of the purified r-DME-M protein using penta-His
MAb. An aliquot of the purified recombinant protein was run in lane 2. Negative (a protein without His tag; BSA) and positive (rED2-III, a protein
with a six-His tag [13]) controls were run in lanes 3 and 4, respectively. Protein molecular mass markers were run in lane 1; their sizes in kDa are
shown to the left. The top and bottom arrows at the right indicate the positions of the r-DME-M protein and the rD2E-III protein, respectively.
Abbreviations: P, prestained protein markers; R, r-DME-M; B, BSA; E, rED2-III. (C) Antibodies induced by the r-DME-M protein interact
specifically with rNS1. Serial 10-fold dilutions of murine sera obtained from animals immunized with PBS (black circles), r-DME-G (open
traingles), r-DME-M (open squares), or DEN-2 rNS1 (black squares) were tested in an ELISA using DEN-2 rNS1 as the capture antigen.
FIG. 2. Expression of r-DME-M protein in E. coli as an MBP fusion. (A) Map of the expression plasmid. The synthetic r-DME-M gene with
a 3 six-His tag-encoding sequence (rDME) was inserted into the BamHI and HindIII sites of plasmid pMALc2x in frame with the MBP-encoding
gene (Mal E). Abbreviations: Ptac, E. coli Ptac promoter; TT, transcriptional terminator; Lac I, lac repressor; Ori and Amp
r, plasmid replication
origin and ampicillin resistance marker, respectively. (B) Coomassie-stained denaturing gel showing the polypeptide profiles of E. coli harboring
the plasmid in panel A, before (lane 3) and after (lane 2) IPTG induction (I, induced; U, noninduced). (C) Localization of the r-DME-M protein
in induced cell lysates. An aliquot of the induced cell lysate prepared by sonication in a native buffer was separated into supernatant (S) and pellet
(P) fractions and analyzed by SDS-PAGE followed by Coomassie staining. In both gels shown in panels B and C, protein molecular mass markers
were run in lane 1; their sizes in kDa are shown to the left. The arrows at the right indicate the position of the rDME-M fusion protein.
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Purification of the r-DME-M protein. As the r-DME-M
protein was only partially soluble with a major proportion in
the insoluble fraction, we proceeded to purify it under dena-
turing conditions to obtain maximal yields. For purification, we
opted to take advantage of the C-terminal six-His tag, rather
than the N-terminal MBP tag, mainly because the Ni-NTA
affinity purification had already been optimized in our labora-
tory for several recombinant six-His-tagged proteins (1, 13). It
should be mentioned here that the r-DME-M protein was
predesigned to carry the six-His tag, and the MBP fusion strat-
egy was adopted mainly to promote expression in E. coli, rather
than to provide an affinity handle for purification. Fractions
collected during different steps of the purification were ana-
lyzed by SDS-PAGE as shown in Fig. 3A. Under the experi-
mental conditions employed, almost all of the induced protein
bound to the column, as evident from a comparison of the
polypeptide profile of the initial lysate loaded on the affinity
matrix (lane 2) with that of the flowthrough material (lane 3).
An extensive wash in the presence of 20 mM imidazole pro-
gressively removed most of the nonspecific contaminants. This
can be seen from a comparison of lanes 4 (initial wash fraction)
and 5 (final wash fraction). Elution of the bound proteins using
250 mM imidazole resulted in the emergence of highly purified
recombinant protein from the column (lanes 6 to 8). We esti-
mate that a 95% purity was achieved on the basis of com-
parison of the protein profiles of the eluted material and the
crude lysate (lane 2). Starting from 1 g induced cell pellet
(equivalent to 250 ml of E. coli culture), we obtained 3.7 mg
purified recombinant protein (pooled fractions in lanes 6 to 8).
This corresponds to a recovery of 69%, as the crude lysate was
estimated to contain 5.4 mg of the recombinant protein,
based on densitometric analysis. A summary of the purification
is presented in Table 1.
Next, we tested the Ni-NTA affinity-purified protein in a
Western blot assay. An aliquot of pooled purified protein was
probed with a commercially available murine penta-His MAb
specific to the engineered six-His tag at the carboxy-terminal
end of the recombinant protein. In this blot, we also included
a previously described six-His-tagged recombinant protein (13)
as a positive control. As a negative control (a protein lacking
the tag), we used bovine serum albumin (BSA). It is evident
from the data shown in Fig. 3B that the penta-His MAb, which
specifically recognizes the six-His-tagged positive control pro-
tein (compare lanes 3 and 4), also recognized the 52-kDa
recombinant protein purified as described in the experiment
shown in Fig. 3A. To further characterize the r-DME-M pro-
tein, we raised murine polyclonal antibodies against it and
tested these in an ELISA using recombinant NS1 as the cap-
ture antigen. The rationale for this experiment was that the
NS1 epitope-derived r-DME-M protein should elicit antibod-
ies capable of recognizing the NS1 protein. This was borne out
by data depicted in Fig. 3C. The data show that the antibodies
elicited by the r-DME-M protein were as good as the antibod-
ies elicited by the r-NS1 protein. Interestingly, sera from mice
immunized with the r-DME-G protein, designed to be IgG
specific, did not show any ELISA reactivity in this assay.
Dengue patient sera recognize the r-DME-M protein. Hav-
ing obtained purified r-DME-M protein, we next proceeded to
ascertain if it would be reactive towards antidengue antibodies
in patient sera. For this, we obtained a large panel (n 	 172)
of suspected dengue patient sera from regions in Sri Lanka
where dengue is endemic. All samples were tested for the
presence of infectious virus and viral RNA. We then analyzed
the presence of antidengue antibodies using the commercially
available Dengue Duo rapid strip test (PanBio Pty Ltd.,
Australia), which detects polyclonal dengue virus-specific an-
tibodies of both IgM and IgG classes (2). The presence of
antidengue IgG antibodies in all these sera was also tested inde-
pendently using our r-DME-G protein described earlier (1).
We next proceeded to evaluate the purified r-DME-M protein
as a diagnostic reagent to detect antidengue IgM antibodies
using this well-characterized serum panel. To this end, we
adapted the in-house ELISA protocol developed previously for
the detection of antidengue antibodies of the IgG class (1). In
this assay, the rDME-M protein was used to capture the IgM
class of antidengue antibodies from patient sera and revealed
using murine anti-human IgM–HRPO conjugate.
The data pertaining to the evaluation of the r-DME-M pro-
tein are summarized in Table 2. Based on the data obtained,
we could categorize the samples broadly into a virus-positive
group (I) and a virus-negative group (II). With regard to the
serology, both groups were heterogenous, as reflected by their
division into subgroups (group I is comprised of subgroups 1 to
TABLE 2. Evaluation of patient sera using the r-DME proteins
Groupa IgM/IgGstatus b
Total no.
of samples
No. positive by:
r-DME c PanBio d
Virus-positive sera
1 IgM/IgG 16 16 16
2 IgM/IgG 5 5 2
3 IgM/IgG 1 1 1
Virus-negative sera
4 IgM/IgG 12 12 12
5 IgM/IgG 37 37 37
6 IgM/IgG 21 21 21
7 IgM/IgG 59 59 59
8 ?e 21 ? ?
a Groups 1 to 3 tested positive for virus; groups 4 to 8 tested negative for virus.
b Presence and absence of IgM or IgG is indicated by  and , respectively.
c The data were obtained using rDME-M and rDME-G (1) separately as
capture antigens in ELISAs to detect IgM and IgG, respectively; samples were
designated as  or  using a cutoff value of 0.25 (representing the mean
absorbance of sera belonging to subgroup 7 plus twice the standard deviation).
d Data were generated using the Dengue Duo IgM & IgG Rapid Strip test
purchased from PanBio Pty., Australia.
e ?, borderline samples, with results from r-DME protein-based in-house
ELISAs and the commercial PanBio tests not in agreement with each other.
TABLE 1. Summary of r-DME-M purification from
1 liter of induced culture
Purification step Total protein(mg)a
Purity
(%)b
Recovery
(%)c
Crude lysated 272 0 100
Ni-NTA affinity 14.8 95 69
Chromatography
a Protein content was determined by the BioRad method, using BSA as standard.
b Purity was assessed by SDS-PAGE analysis.
c The amount of r-DME-M protein in the crude lysate (which was estimated to be
5.4 mg by densitometric analysis) was designated as 100%.
d The purification was done using a 250-ml culture (wet cell weight of 1 g).
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3; group II is comprised of subgroups 4 to 8). Table 3 presents
serum-wise data for group I samples (n 	 22). All these sera
contained viral RNA, and infectious virus could be isolated
from all but one sample of this group. A total of six samples (all
five of subgroup 2 plus the single one from subgroup 3) were
found to contain IgM antibodies. Out of these six, the PanBio
strip test identified three samples (two from subgroup 2 and
the single subgroup 3 sample) as IgM. With regard to IgG,
only one sample (subgroup 3) was found to be positive; this was
corroborated by the PanBio test. The remaining samples (sub-
group 1; n 	 16) were negative for both IgM and IgG. Once
again, these results were borne out by the PanBio test.
The samples comprising group II (n	 150) were all found to
be virus/RNA. Of the 129 samples, represented collectively
by subgroups 4 to 7, we could detect the presence of IgM in 49
samples (12 samples of subgroup 4 plus 37 samples of sub-
group 5) and IgG in 33 samples (12 samples of subgroup 4 plus
21 samples of subgroup 6), using the r-DME-G-based IgG
ELISA (1). Samples in subgroup 7 were all IgM/IgG and
are presumably “normal,” as all of them tested negative in the
virus isolation and reverse transcription-PCR assays as well.
With regard to the PanBio test, 19 samples of group I (16 from
subgroup 1, 2 from subgroup 2, and the single sample from
subgroup 3) and all samples of subgroups 4 to 7 (n 	 129)
yielded results that were identical to those obtained using the
r-DME-based IgM and IgG ELISAs.
For samples in subgroup 8 (n 	 21), the results of the
r-DME-based ELISAs did not agree with those of the PanBio
test. It must be pointed out that neither virus nor viral RNA
could be detected in all of these “indeterminate” samples.
With regard to IgM status, a closer examination of the ELISA
data revealed that the PanBio and the r-DME-M-based ELISA
results were not consistent with each other for 14 of these 21
indeterminate samples. Similarly, the remaining sera were in-
consistent with respect to IgG status. Of the 14 indeterminate
samples above, seven sera, which were identified as IgM by
the PanBio test, were not picked up by the r-DME-M-based
IgM ELISA. Likewise, the remaining seven, which tested pos-
itive using the r-DME-M protein, scored negative in the
PanBio test. An inspection of the ELISA absorbances of these
14 sera revealed that all of them manifested borderline reac-
tivity towards the r-DME-M protein, as depicted in Fig. 4. For
comparison, this figure also includes the three IgM samples
of subgroup 2, which were missed by the PanBio test. Similarly,
the discrepancies in IgG status using the PanBio test and our
previously developed r-DME-G-based ELISA could be traced
to borderline samples (data not shown). The overall compar-
ative analysis of our data with the PanBio results suggests that
there is an excellent agreement between the r-DME-based
ELISA and the PanBio tests, with 86% (148 out of 172) of
the samples analyzed giving identical results. Further, the r-
DME-M-based IgM ELISA picked up three additional sam-
ples (group I, subgroup 2) which the PanBio test failed to
identify. The fact that these three samples were virus/RNA
suggests that the r-DME-M-based IgM ELISA test is more
effective in early diagnosis of dengue infection.
The r-DME-M protein as a dengue diagnostic reagent. We
next sought to devise a rapid test that might be useful in
FIG. 4. Analysis of indeterminate sera with widely ranging r-DME-M
reactivities. The scatter diagram displays the reactivities (absorbance at
450 nm) of sera manifesting weak and strong reactivities towards the
r-DME-M protein used as the capture antigen in the in-house IgM
ELISA. The IgM status of the sera determined by the PanBio strip test
(PanBio) or the in-house IgM ELISA (r-DME-M) is shown in the inset;
the subgroup, with reference to Table 2, to which the serum belongs is
shown in parentheses. The dotted line indicates the cutoff absorbance
(0.25 at 450 nm) used to designate samples as either positive or negative.
TABLE 3. Single serum profiles of dengue virus-positive sera
Sample no.
and ID
Identity based on: IgM/IgG status a
RT-PCR f Virusisolation r-DME
b PanBio c
1, D176 DEN-2 DEN-2 IgM/IgG IgM/IgG
2, D192 DEN-2 DEN-2 IgM/IgG IgM/IgG
3, D211 DEN-2 DEN-2 IgM/IgG IgM/IgG
4, D223 DEN-2 DEN-2 IgM/IgG IgM/IgG
5, D225 DEN-2 DEN-2 IgM/IgG IgM/IgG
6, D226 DEN-2 DEN-2 IgM/IgG IgM/IgG
7, D086 DEN-2 DEN-2 IgM/IgG IgM/IgG
8, D168 DEN-2 DEN-2 IgM/IgG IgM/IgG
9, D173 DEN-2 DEN-2 IgM/IgG IgM/IgG
10, D174 DEN-2 DEN-2 IgM/IgG IgM/IgG
11, D039 DEN-3 DEN-3 IgM/IgG IgM/IgG
12, D019 DEN-2 DEN-2 IgM/IgG IgM/IgG
13, D119 DEN-2 DEN-2 IgM/IgG IgM/IgG
14, D092 DEN-3 DEN-3 IgM/IgG IgM/IgG
15, D022 DEN-2 DEN-2 IgM/IgG IgM/IgG
16, D030 DEN-2 DEN-2 IgM/IgG IgM/IgG
17, d 0075 DEN-2 DEN-2 IgM/IgG IgM/IgG
18, d D065 DEN-2 DEN-2 IgM/IgG IgM/IgG
19, D016 DEN-2 DEN-2 IgM/IgG IgM/IgG
20, D027 DEN-2 DEN-2 IgM/IgG IgM/IgG
21, D011 DEN-2 —e IgM/IgG IgM/IgG
22,d D068 DEN-2 DEN-2 IgM/IgG IgM/IgG
a Presence and absence of IgM or IgG are indicated by  and  superscripts,
respectively.
b The data were obtained using rDME-M and rDME-G (1) separately as
capture antigens in ELISAs to detect IgM and IgG, respectively; samples were
designated as  or  using a cutoff value of 0.25 (representing the mean
absorbance of sera belonging to subgroup 7 [Table 2] plus twice the standard
deviation).
c Data were generated using Dengue Duo IgM & IgG Rapid Strip test pur-
chased from PanBio Pty., Australia.
d Virus-positive samples containing IgM antibodies (IgM in bold) picked up
by the r-DME-M-based ELISA but missed by the PanBio test.
e —, virus could not be isolated successfully from this sample.
f RT-PCR, reverse transcription-PCR.
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identifying the presence of antidengue antibodies in patient
sera under field conditions, that is, without having to use any
laboratory facilities. Accordingly, a rapid strip test, shown in
Fig. 5A, was designed. Across this strip we coated r-DME-M
protein as a streak. We placed a second streak of murine
polyclonal anti-r-DME-M sera. To perform the test, we mixed
the patient serum with gold-labeled r-DME-M protein in a
microtiter well, dipped the lower end of the strip into this
mixture, and allowed sufficient time for the sample to rise to
the level of the absorbent pad by capillary action. Shown in
Fig. 5B are the results of typical negative and positive tests. In
the negative (-) sample that did not contain any antidengue
antibodies (IgM/IgG, using the PanBio test), a single pale
pink line appeared (Fig. 5A). This represents free gold-labeled
r-DME-M protein captured by the murine polyclonal antibod-
ies coated at the control line. In the case of the dengue anti-
body-positive (either IgM/IgG or IgM/IgG, using the
PanBio test) serum sample, however, a second pale pink line
appeared at the test line. This represents the gold-labeled
r-DME-M protein–antidengue antibody complex captured by
unlabeled r-DME-M coated at the test line. The results of the
strip test showed that the r-DME-M protein could indeed be
adapted to a rapid test format for the detection of dengue-
specific antibodies.
DISCUSSION
Dengue diagnosis based on antibody identification has
emerged as the most practical approach (7). Most methods of
antibody detection rely on the use of whole dengue virus an-
tigens. As mentioned earlier, the serodiagnosis of dengue
based on antibody detection is complicated by the existence of
cross-reactive antigenic determinants shared by members of
the Flaviviridae family (6, 7). Apart from compromising sensi-
tivity and specificity, the preparation of whole virus antigen is
associated with biohazard risk and high production costs.
While replacing the whole virus antigen with a recombinantly
produced viral protein can eliminate the safety risk, it may not
necessarily address the cross-reactivity and cost considerations.
This was underscored by a recent report which showed that a
mixture of recombinant E proteins (of all four DEN serotypes)
could effectively replace the whole virus antigen in a commer-
cial test but failed to eliminate cross-reactivity with antibodies
to other flaviviruses (2). Further, this test also did not effec-
tively address the cost factor, as it used four recombinant
proteins produced using an insect cell culture system. Thus,
there is a need for development of diagnostic tests that incor-
porate not only a high degree of sensitivity and specificity of
detection but also safety and cost-effectiveness as well. The
use of a customized, recombinant antigen that can be over-
expressed in E. coli may offer an alternative that effectively
addresses the concerns mentioned above. Therefore, the major
objective of this study was to design an IgM-specific recombi-
nant multiepitope protein and evaluate its potential in the
detection of antidengue IgM antibodies. To this end, we ap-
plied our recently developed strategy of creating customized
antigens to develop a multiepitope protein, r-DME-M, de-
signed to detect IgM-specific antidengue antibodies to aid in
early diagnosis of primary dengue infections. This strategy
depends on fusing together linear, immunodominant epitopes
using flexible linkers.
A search for immunodominant IgM-specific dengue epitopes
revealed a single linear epitope which mapped to the amino-
terminal 15 residues of the DEN-2 NS1 protein (11). Presum-
ably, most IgM-specific epitopes may be conformational, and
this may perhaps explain the paucity of information regarding
linear IgM-specific dengue epitopes. However, in an effort to
include additional IgM-specific epitopes in designing the r-
DME-M protein, we compared the amino-terminal sequences
of the NS1 proteins of the remaining three DEN serotypes with
that of the DEN-2 NS1 protein. This revealed a high degree of
sequence homology among all four DEN serotypes, prompting
the notion that the amino termini of the NS1 proteins of all
four DEN serotypes represent potential IgM-specific epitopes.
Thus, we created the synthetic gene, r-DME-M, encoding all four
of these NS1 epitopes, in which adjacent epitopes were joined
using flexible tetraglycyl linkers. Glycine was used as the linker
residue, as it can provide flexibility owing to its lack of a

-carbon (18). Computer modeling analyses showed that the
r-DME-M protein adopts a structure in which all the epitopes
are freely accessible, suggesting that each of them would be
able to collectively contribute to the overall IgM specificity of
the molecule. We engineered a six-His tag-encoding sequence
at the 3 end of the r-DME-M gene to facilitate one-step affinity
purification of the expressed protein. We failed to express this
FIG. 5. Design and use of the rapid strip assay to detect antidengue
antibodies using the r-DME-M protein. (A) Schematic representation
of the strip test template. The strip consists of a nitrocellulose mem-
brane mounted on a plastic support. The shaded portion at the top
represents the absorbent pad. The test line (T, indicated by the solid
line) denotes the position on the strip at which the r-DME-M protein
(indicated by the black circle) is immobilized as a thin line. The control
line (C, indicated by the dashed line) denotes the position on the strip
at which murine anti-r-DME-M polyclonal serum (indicated by the
dotted Y) is coated as a thin line. Shown below is the sample receptacle
containing the test serum mixed with gold-labeled r-DME-M (indi-
cated by the black star). Antidengue IgM antibody (indicated by the
solid Y) if present will form a complex with the gold-labeled r-DME-M
in the sample well. The dotted arrow at the left side of the strip
template indicates the direction of sample migration during the test.
(B) Depiction of the actual results of the strip test performed with sera
that lack () or contain () antidengue IgM antibodies. A schematic
representation of the complexes formed at the T and C lines is shown
to the right.
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gene using the pQE60 vector. This is presumably a reflection of
the small size (88 aa residues) of the protein it encodes (5).
This notion appears consistent with our observation that this
same gene could be expressed successfully when fused to the
MBP-encoding malE gene. Analysis of the Ni-NTA-purified
r-DME-M (MBP fusion) protein by SDS-PAGE showed that a
high degree of purity, 95%, had been achieved in a single
step. Our data show that starting from a 1-liter culture of
induced cells, 15 mg of purified protein, representing a
69% recovery from the crude lysate, can be obtained. Puri-
fied r-DME-M protein could be detected in a Western blot
assay using anti-His MAb, consistent with its ability to bind
Ni-NTA matrix.
Since one of the major objectives of this study was to inves-
tigate the potential of the r-DME-M protein as a diagnostic
antigen for the early detection of dengue infections, we tested
the ability of the r-DME-M protein to detect antidengue IgM
antibodies in an in-house ELISA. Using our recombinant pro-
tein as the capture antigen and dengue patient serum as the
test sample, captured antidengue IgM antibodies were de-
tected using murine anti-human IgM–HRPO conjugate in con-
junction with TMB substrate. We tested a panel of 172 serum
samples drawn from patients in Sri Lanka suspected of dengue
infection. Prior to using this panel for the evaluation of r-
DME-M, we characterized the samples for the presence and
type of dengue virus infection (by virus isolation and RT-PCR)
and antidengue antibodies (using the commercially available
PanBio test). We also determined the presence of antidengue
IgG antibodies in these sera using our IgG-specific r-DME-G
protein developed recently (1). We then evaluated the utility of
the r-DME-M protein developed in this study to detect the
presence of antidengue antibodies of the IgM class in this
serum panel. This analysis showed that 80 (subgroups 6 and 7)
(Table 2) out of the 172 sera which were IgM based on the
PanBio test displayed no significant reactivity towards the r-
DME-M protein in our in-house ELISA test. All these sera
were virus negative. As 21 (corresponding to subgroup 6)
(Table 2) out of these 80 sera were IgG (based on both the
PanBio test as well as their reactivity to the IgG-specific r-
DME-G protein), we interpret the remaining 59 (subgroup 7 in
Table 2) sera to be “normal.” The reactivities of these 59
samples were used to compute the cutoff ELISA absorbance
value (equivalent to an OD450 of 0.25) to designate the re-
maining samples as either positive or negative. Based on this
cutoff, 55 sera (corresponding to subgroups 2 to 5) were found
to be IgM. All but 3 out of these 55 sera could be corrobo-
rated as IgM using the PanBio test. We believe that these
three sera (subgroup 2 in Table 2) which manifested significant
reactivity towards the r-DME-M protein (Fig. 4) are indeed
IgM despite their not being scored positive for IgM antibod-
ies in the PanBio test. Our conclusion stems from the fact that
our in-house ELISA relies on an IgM-specific NS1 epitope-
based r-DME-M antigen while the PanBio test utilizes a cock-
tail of E proteins to detect antidengue IgM antibodies. Our
preliminary data suggest that the NS1-based r-DME-M protein
offers better sensitivity in the early detection of IgM antibod-
ies. The observation that these sera were also virus positive
lends credence to this notion. Subgroup 1 sera (n 	 16), which
were also virus positive, however, tested negative for both IgM
and IgG in both the PanBio as well as the r-DME-M (or
r-DME-G) protein-based assays. These presumably represent
samples from patients still in the viremic phase. Results for 21
sera (subgroup 8) were not consistent between the PanBio test
on the one hand and the r-DME-M (or r-DME-G) protein-
based assay on the other. These were borderline samples
whose ELISA reactivities were close to the cutoff. It is likely
that the borderline sera that tested positive using the
r-DME-M protein contained predominantly anti-NS1 antibod-
ies and represent “early” samples that were missed by the
PanBio test designed to detect anti-E antibodies. A two-copy
r-DME-M protein yielded essentially the same results (data
not shown).
Interestingly, of the 55 IgM-positive sera samples referred to
above, 13 sera (corresponding to subgroups 3 and 4 in Table 2)
were also positive for IgG antibodies, while the remaining were
IgG negative. Given that we have used anti-human IgM–
HRPO to detect the antidengue IgM antibodies, this observa-
tion suggests that the r-DME-M protein is capable of specifi-
cally interacting with the IgM antibodies and that this
interaction is not affected by the presence of antidengue IgG
antibodies. This notion is further strengthened by the observed
lack of reactivity of the IgG subgroup 6 sera (n	 21) towards
the r-DME-M protein (Table 2). The overall comparative anal-
ysis of our data with the PanBio results suggests that there is an
excellent agreement between the r-DME-protein-based ELISAs
and the PanBio test, with 86% (148 out of 172) of the samples
analyzed giving identical results. With reference to our in-house
NS1 epitope-derived r-DME-M-based IgM ELISA, the E pro-
tein-based PanBio test was found to be95% sensitive in detect-
ing antidengue IgM antibodies.
The standard IgM antibody capture ELISA routinely used to
detect antidengue IgM antibodies typically uses anti-human
IgM to capture serum IgM, which in turn is detected using a
mixture of all four DEN whole-virus antigens in conjunction
with an antidengue antibody conjugate (16). This entails the
production of two different antibodies and all four DEN anti-
gens. The PanBio test is based on a similar antibody capture
format, with some minor variations. In contrast, the in-house
ELISA we have described uses just a single customized recom-
binant antigen designed to directly bind antidengue IgM anti-
bodies in conjunction with a secondary antibody conjugate. In
this context, it is noteworthy that the in-house ELISA results
are in complete agreement with the PanBio test results.
Having shown that the r-DME-M protein does indeed have
the capacity to detect antidengue IgM antibodies, we have used
it to devise a simple, rapid strip test that may be of use in a field
setting. This test consists of incubating the patient serum with
gold-labeled r-DME-M protein and capturing the gold-labeled
antigen–antidengue antibody complex using nonlabeled r-DME-
M immobilized on a nitrocellulose strip. The captured complex
is visualized as a pink line on the test strip. In conjunction with
our previously developed r-DME-G protein, this strip test can
be modified to enable simultaneous detection of both IgM and
IgG antibodies. Further evaluation of the r-DME-M protein
must await the availability of more patient sera. We would also
need to test our recombinant protein against antibodies to
other infectious pathogens (such as those causing Japanese
encephalitis, yellow fever, malaria, and typhoid) to evaluate its
specificity. The D2 NS1-P1 peptide, on which the r-DME-M
protein is based, has been shown to be uniquely specific for
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sera from dengue patients, showing no reactivity towards JE
patient sera (11). While it is very likely that this specificity is
preserved in the r-DME-M protein, it needs to be tested
experimentally. We have been unable to address this issue at
the present time due to the nonavailability of JE and yellow
fever patient sera. It is also necessary to identify additional
linear, immunodominant IgM-specific epitopes. This will en-
able the design of improved versions of r-DME-M protein with
enhanced diagnostic potential. In conclusion, our approach to
creating recombinant antigens with tailored specificity to either
the IgM (this study) or IgG (1) class of antibodies coupled to
E. coli-based overexpression and simple one-step purification
could be a precursor to developing alternate diagnostic options
that may eliminate the concerns associated with currently avail-
able tests based on whole-virus antigens. This would be a strategy
not restricted to the detection of dengue infections alone.
ACKNOWLEDGMENTS
This work has been supported by institutional core funds and a grant
from the Ministry of Defense, Government of India. R.A. is a Senior
Research Fellow supported by the Indian Council of Scientific and
Industrial Research.
REFERENCES
1. AnandaRao, R., S. Swaminathan, S. Fernando, A. M. Jana, and N. Khanna.
2005. A custom-designed recombinant multiepitope protein as a dengue
diagnostic reagent. Protein Expr. Purif. 41:136–141.
2. Cuzzubbo, A. J., T. P. Endy, A. Nisalak, S. Kalyanarooj, D. W. Vaughn, S. A.
Ogata, D. E. Clements, and P. L. Devine. 2001. Use of recombinant envelope
proteins for serological diagnosis of dengue virus infection in an immuno-
chromatographic assay. Clin. Diagn. Lab. Immunol. 8:1150–1155.
3. Falconar, A. K. I., P. R. Young, and M. A. Miles. 1994. Precise location of
sequential dengue virus subcomplex and complex B cell epitopes on the
nonstructural-1 glycoprotein. Arch. Virol. 137:315–326.
4. Garcia, G., D. W. Vaughn, and R. M. del Angel. 1997. Recognition of
synthetic oligopeptides from nonstructural proteins NS1 and NS3 of den-
gue-4 virus by sera from dengue virus-infected children. Am. J. Trop. Med.
Hyg. 56:466–470.
5. Goeddel, D. V. 1990. Systems for heterologous gene expression. Methods
Enzymol. 185:3–7.
6. Groen, J., P. Koraka, J. Velzing, C. Copra, and A. D. M. E. Osterhaus.
2000. Evaluation of six immunoassays for detection of dengue virus-
specific immunoglobulin M and G antibodies. Clin. Diagn. Lab. Immunol.
7:867–871.
7. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol.
Rev. 11:480–496.
8. Gubler, D. J. 2002. Epidemic dengue/dengue hemorrhagic fever as a public
health, social and economic problem in the 21st century. Trends Microbiol.
10:100–103.
9. Gubler, D. J. 2004. Cities spawn epidemic dengue viruses. Nat. Med. 10:
129–130.
10. Hales, S., N. de Wet, J. Maindonald, and A. Woodward. 2002. Potential effect
of population and climate changes on global distribution of dengue fever: an
empirical model. Lancet 360:830–834.
11. Huang, J. H., J. J. Wey, Y. C. Sun, C. Chin, L. J. Chien, and Y. C. Wu. 1999.
Antibody responses to an immunodominant nonstructural 1 synthetic pep-
tide in patients with dengue fever and dengue hemorrhagic fever. J. Med.
Virol. 57:1–8.
12. Innis, B. L., V. Thirawuth, and C. Hemachudha. 1989. Identification of
continuous epitopes of the envelope glycoprotein of dengue type 2 virus.
Am. J. Trop. Med. Hyg. 40:676–687.
13. Jaiswal, S., N. Khanna, and S. Swaminathan. 2004. High-level expression
and one-step purification of recombinant dengue virus type 2 envelope
domain III protein in Escherichia coli. Protein Expr. Purif. 33:80–91.
14. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of
the head of bacteriophage T4. Nature 227:680–685.
15. Megret, F., J. P. Hugnot, A. Falconar, M. K. Gentry, D. M. Morens, J. M.
Murray, J. J. Schlesinger, P. J. Wright, P. Young, M. H. V. van Regenmortel,
and V. Deubel. 1992. Use of recombinant fusion proteins and monoclonal
antibodies to define linear and discontinuous antigenic sites on the dengue
envelope glycoprotein. Virology 187:480–491.
16. Nawa, M., K.-I. Yamada, T. Takasaki, T. Akatsuka, and I. Kurane. 2000.
Serotype-cross-reactive immunoglobulin M responses in dengue virus infec-
tions determined by enzyme-linked immunosorbent assay. Clin. Diagn. Lab.
Immunol. 7:774–777.
17. Nimmannitya, S. 1997. Dengue hemorrhagic fever: diagnosis and manage-
ment, p. 133–145. In D. J. Gubler and G. Kuno (ed.), Dengue and dengue
hemorrhagic fever. CAB International, Wallingford, United Kingdom.
18. Robinson, C. R., and R. T. Sauer. 1998. Optimizing the stability of single-
chain proteins by linker length and composition mutagenesis. Proc. Natl.
Acad. Sci. USA 95:5929–5934.
19. Shu, P. Y., and J. H. Huang. 2004. Current advances in dengue diagnosis.
Clin. Diagn. Lab. Immunol. 11:642–650.
20. Trirawatanapong, T., B. Chandran, R. Putnak, and R. Padmanabhan. 1992.
Mapping of a region of dengue virus type-2 glycoprotein required for binding
by a neutralizing monoclonal antibody. Gene 116:139–150.
21. World Health Organization. 1997. Dengue haemorrhagic fever: diagnosis,
treatment, prevention and control, 2nd ed. World Health Organization,
Geneva, Switzerland.
22. Wu, H.-C., Y.-L. Huang, T.-T. Chao, J.-T. Jan, J.-L. Huang, H.-Y. Chiang,
C.-C. King, and M.-F. Shaio. 2001. Identification of B-cell epitope of dengue
virus type 1 and its application in diagnosis of patients. J. Clin. Microbiol.
39:977–982.
23. Wu, H.-C., M.-Y. Jung, C.-Y. Chiu, T.-T. Chao, S.-C. Lai, J.-T. Jan, and
M.-F. Shaio. 2003. Identification of a dengue virus type 2 (DEN-2) serotype-
specific B-cell epitope and detection of DEN-2-immunized animal serum
samples using an epitope-based peptide antigen. J. Gen. Virol. 84:2771–
2779.
VOL. 13, 2006 RECOMBINANT MULTIEPITOPE PROTEIN IN DENGUE DIAGNOSIS 67
 o
n
 June 15, 2017 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
